FDA-Approved PARP Inhibitor Shows 80% Tumor Reduction in EBV-Driven Lymphoma
Key Insights
Researchers at The Wistar Institute discovered that FDA-approved PARP1 inhibitors (search) can effectively halt Epstein-Barr virus (search)-driven lymphoma (search) growth through a novel mechanism.
The PARP inhibitor talazoparib demonstrated an 80% reduction in tumor growth in mouse models without causing typical DNA damage.
The drug works by disrupting the interaction between viral protein EBNA2 (search) and oncogene MYC (search), blocking the virus's ability to activate cancer-promoting genes.
Researchers at The Wistar Institute have discovered that FDA-approved PARP1 inhibitors (search) can effectively combat Epstein-Barr virus (search) (EBV)-driven lymphomas through a previously unknown mechanism, offering new hope for treating these aggressive cancers. The findings, published in the Journal of Medical Virology, demonstrate that these drugs work differently in viral cancers compared to their established use in other malignancies.
Novel Mechanism of Action
"We've uncovered a completely different mechanism for how PARP inhibitors work in EBV-positive cancers," said Dr. Italo Tempera, Associate Professor in the Genome Regulation and Cell Signaling Program at Wistar's Ellen and Ronald Caplan Cancer Center and senior author of the study. "Instead of preventing DNA damage from repairing itself in the tumors, like these drugs do in other cancers, they essentially cut off the virus's ability to hijack cellular machinery to drive cancer growth."
The research team focused on PARP1 (search), a cellular protein known primarily for DNA repair but which also enables EBV to manipulate gene activity in infected cells. "Think of PARP1 as a key that opens up DNA to make certain genes readable," explained Dr. Tempera. "EBV uses this key to unlock cancer-promoting genes. When we block PARP1, we're essentially taking away the key so the virus can't get in and use our DNA for its own purposes."
Striking Preclinical Results
Using a mouse model of EBV-driven lymphoma (search), researchers treated animals with talazoparib (BMN 673), a PARP inhibitor already approved for breast cancer (search) treatment. The results were remarkable: treated mice showed an 80% reduction in tumor growth, and the cancer's ability to spread to other organs was significantly reduced.
Importantly, analysis of the tumors revealed no increase in DNA damage in treated animals—the hallmark of how PARP inhibitors typically work in other cancers. Instead, the team discovered that PARP1 (search) inhibition disrupted a critical partnership between the viral protein EBNA2 (search) and the cellular oncogene MYC (search).
"EBNA2 (search) is like the conductor of an orchestra, directing cellular genes to play a cancer symphony," said Dr. Tempera. "It specifically turns on MYC (search), which is one of the most important cancer-promoting genes. When we inhibit PARP1 (search), EBNA2 can't effectively activate MYC anymore, and the whole cancer program falls apart."
Addressing an Unmet Medical Need
EBV infects over 90% of the global population. While most people with the virus remain symptom-free, immunocompromised individuals such as people with HIV and transplant recipients have an increased risk of EBV causing several types of cancer, including various lymphomas and carcinomas. Despite the virus's clear role in driving these malignancies, no specific therapies currently target EBV-driven cancer pathways.
Accelerated Clinical Potential
The findings have significant therapeutic implications. Because PARP inhibitors are already FDA-approved with well-established safety profiles, the path to clinical application could be accelerated compared to developing entirely new drugs. "This isn't just a new use for an existing drug - it represents a completely different mechanism of action in a viral cancer," noted Dr. Tempera.
Broader Applications Under Investigation
The research suggests this approach might work beyond EBV-associated lymphomas. The team is now investigating whether PARP inhibitors could be effective against other EBV-driven cancers, including nasopharyngeal and gastric carcinomas. Additionally, given EBV's suspected role in autoimmune diseases, the researchers are exploring whether PARP1 (search)'s regulation of viral gene expression might contribute to these conditions.
"This work really showcases the power of understanding fundamental viral biology," said Dr. Tempera. "We're taking insights from basic virology research and translating them into potential therapies. With further development, this approach could provide new hope for patients with EBV-associated cancers who currently have limited treatment options."
The work was supported by National Institutes of Health grants R01 AI130209 and R01 GM124449 to Dr. Tempera, along with additional NIH funding and Core Grant P30 CA010815-53.